KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Cash (2016 - 2025)

Globus Medical's Change in Cash history spans 15 years, with the latest figure at $154.4 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 4.51% year-over-year to $154.4 million; the TTM value through Dec 2025 reached -$258.3 million, down 181.44%, while the annual FY2025 figure was -$258.3 million, 181.44% down from the prior year.
  • Change in Cash reached $154.4 million in Q4 2025 per GMED's latest filing, up from $142.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $212.3 million in Q3 2024 to a low of -$323.2 million in Q1 2025.
  • Average Change in Cash over 5 years is $14.3 million, with a median of $46.5 million recorded in 2022.
  • The largest YoY upside for Change in Cash was 7165.24% in 2021 against a maximum downside of 1405.86% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$168.8 million in 2021, then soared by 109.62% to $16.2 million in 2022, then soared by 1055.4% to $187.7 million in 2023, then fell by 13.85% to $161.7 million in 2024, then decreased by 4.51% to $154.4 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Change in Cash are $154.4 million (Q4 2025), $142.3 million (Q3 2025), and -$231.8 million (Q2 2025).